Determination of the active metabolite of prulifloxacin in human plasma by liquid chromatography-tandem mass spectrometry

被引:28
作者
Guo, LX
Qi, ML [1 ]
Jin, X
Wang, P
Zhao, HQ
机构
[1] Beijing Inst Technol, Sch Sci, Dept Chem, Beijing 100081, Peoples R China
[2] Shenyang Pharmaceut Univ, Sch Pharm, Dept Analyt Chem, Shenyang 110016, Peoples R China
[3] Shenyang Pharmtech Pharmaceut R&D Co Ltd, Shenyang 110016, Peoples R China
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2006年 / 832卷 / 02期
关键词
prulifloxacin; ulifloxacin; liquid chromatography-tandem mass spectrometry; human plasma;
D O I
10.1016/j.jchromb.2006.01.026
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A liquid chromatographic-tandem mass spectrometric method (LC-MS/MS) for the determination of ulifloxacin, the active metabolite of prulifloxacin, in human plasma is described. After sample preparation by protein precipitation with methanol, ulifloxacin and ofloxacin (internal standard) were chromatographically separated on a C-18 column using a mobile phase consisting of methanol, water and formic acid (70:30:0.2, v/v/v) at a flow rate of 0.5 ml/min and then were detected using MS/MS by monitoring their precursor-to-product ion transitions, m/z 350 -> m/z 248 for ulifloxacin and m/z 362 -> m/z 261 for ofloxacin, in selected reaction monitoring (SRM) mode. Positive electrospray ionization was used for the ionization process. The linear range was 0.025-5.0 mu g/ml for ulifloxacin with a lower limit of quantitation of 0.025 mu g/ml. Within- and between-run precision was less than 6.6 and 7.8%, respectively, and accuracy was within 2.0%. The recovery ranged from 92.1 to 98.2% at the concentrations of 0.025, 0.50 and 5.0 mu g/ml. Compared with the reported LC method, the present LC-MS/MS method can directly determine the ulifloxacin in human plasma without any need of derivatization. The present method has been successfully used for the pharmacokinetic studies of a prulifloxacin formulation product after oral administration to healthy volunteers. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:280 / 285
页数:6
相关论文
共 7 条
  • [1] Prulifloxacin
    Keam, SJ
    Perry, CM
    [J]. DRUGS, 2004, 64 (19) : 2221 - 2234
  • [2] PHARMACOKINETICS AND SAFETY OF NM441, A NEW QUINOLONE, IN HEALTHY MALE-VOLUNTEERS
    NAKASHIMA, M
    UEMATSU, T
    KOSUGE, K
    OKUYAMA, Y
    MORINO, A
    OZAKI, M
    TAKEBE, Y
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 34 (09) : 930 - 937
  • [3] OKUHAMA Y, 1997, ARZNEIMITTEL-FORSCH, V47, P276
  • [4] OKUHAMA Y, 1997, ARZNEIMITTEL-FORSCH, V47, P293
  • [5] OKUHAMA Y, 1997, ARZNEIMITTEL-FORSCH, V47, P285
  • [6] Picollo R, 2003, ARZNEIMITTEL-FORSCH, V53, P201
  • [7] Tougou K, 1998, DRUG METAB DISPOS, V26, P355